BUPHENYL POWDER Rx
Generic Name and Formulations:
Sodium phenylbutyrate 940mg/gram; contains sodium 11.7g/100g of pwd.
Indications for BUPHENYL POWDER:
Adjunct in the chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase, including neonatal-onset deficiency and late-onset disease with a history of hyperammonemic encephalopathy.
Adults and Children:
<20kg: use powder. Take in equally divided doses with each meal or feeding. Mix powder with food or liquid. <20kg: 450–600mg/kg/day. ≥20kg: 9.9–13g/m2/day. Max 20g/day.
Restrict dietary protein, may need to supplement with essential amino acids. CHF. Sodium retention with edema. Renal or hepatic insufficiency. Inborn errors of beta oxidation. Monitor serum levels of phenylbutyrate and metabolites, phenylacetate and phenylacetylglutamine. Plasma levels of ammonia, arginine, branched-chain amino acids, serum proteins: maintain within normal levels; plasma glutamine: maintain at <1000μmol/L. Elderly. Pregnancy (Cat.C). Nursing mothers.
May be potentiated by probenecid. Corticosteroids may increase plasma ammonia levels. Hyperammonemia possible with haloperidol and valproic acid.
Amenorrhea/menstrual dysfunction, acidosis, hypoalbuminemia, anemia, alkalosis, hyperchloremia, hypophosphatemia, increased alkaline phosphatase, increased liver transaminases, leukopenia, leukocytosis, decreased appetite, body odor, bad taste, taste aversion, others.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities